ETF overview
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.
Fund facts
- Expense ratio
- 0.60%
- Fund assets
- 1.13B USD (all share classes)
- Issuer
- First Trust
- Inception date
- Sep 20, 2016
- Number of holdings
- 50
Breakdown
Holdings (50)
| Name | Ticker | Weight |
|---|---|---|
| AbbVie Inc. | ABBV | 7.92% |
| Eli Lilly and Company | LLY | 7.73% |
| Pfizer Inc. | PFE | 7.39% |
| Merck & Co., Inc. | MRK | 7.02% |
| Johnson & Johnson | JNJ | 6.84% |
| Viatris Inc. | VTRS | 4.02% |
| Biogen Inc. | BIIB | 3.82% |
| Gilead Sciences, Inc. | GILD | 3.80% |
| Zoetis Inc. | ZTS | 3.66% |
| Amgen Inc. | AMGN | 3.58% |
| and 37 more | ||
Similar ETFs
- Invesco Pharmaceuticals ETFPJP · Overlap 55% · Expense ratio 0.58%
- Portfolio Building Block World Pharma and Biotech Index ETFPBPH · Overlap 52% · Expense ratio 0.13%
- iShares U.S. Healthcare ETFIYH · Overlap 48% · Expense ratio 0.37%
- Vanguard Health Care ETFVHT · Overlap 46% · Expense ratio 0.09%
- State Street Health Care Select Sector SPDR ETFXLV · Overlap 46% · Expense ratio 0.08%
- Fidelity MSCI Health Care Index ETFFHLC · Overlap 45% · Expense ratio 0.08%
- iShares U.S. Pharmaceuticals ETFIHE · Overlap 40% · Expense ratio 0.37%
- Invesco Nasdaq Biotechnology ETFIBBQ · Overlap 39% · Expense ratio 0.19%
Overlap is the share of assets the two funds hold in common.
Historical returns do not guarantee future returns. This is not investment advice.
- Expense ratio
- 0.60%
- Fund assets
- 1.13B USD (all share classes)
- Issuer
- First Trust
- Inception date
- Sep 20, 2016
- Number of holdings
- 50
| Name | Ticker | Weight |
|---|---|---|
| AbbVie Inc. | ABBV | 7.92% |
| Eli Lilly and Company | LLY | 7.73% |
| Pfizer Inc. | PFE | 7.39% |
| Merck & Co., Inc. | MRK | 7.02% |
| Johnson & Johnson | JNJ | 6.84% |
| Viatris Inc. | VTRS | 4.02% |
| Biogen Inc. | BIIB | 3.82% |
| Gilead Sciences, Inc. | GILD | 3.80% |
| Zoetis Inc. | ZTS | 3.66% |
| Amgen Inc. | AMGN | 3.58% |
| and 37 more | ||
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.
- Invesco Pharmaceuticals ETFPJP · Overlap 55% · Expense ratio 0.58%
- Portfolio Building Block World Pharma and Biotech Index ETFPBPH · Overlap 52% · Expense ratio 0.13%
- iShares U.S. Healthcare ETFIYH · Overlap 48% · Expense ratio 0.37%
- Vanguard Health Care ETFVHT · Overlap 46% · Expense ratio 0.09%
- State Street Health Care Select Sector SPDR ETFXLV · Overlap 46% · Expense ratio 0.08%
- Fidelity MSCI Health Care Index ETFFHLC · Overlap 45% · Expense ratio 0.08%
- iShares U.S. Pharmaceuticals ETFIHE · Overlap 40% · Expense ratio 0.37%
- Invesco Nasdaq Biotechnology ETFIBBQ · Overlap 39% · Expense ratio 0.19%
Overlap is the share of assets the two funds hold in common.
Unlock all ETF data
Sign up for FreeUnlock all ETF data
Sign up for Free